Teva Announces FDA Approval of QNASL for Children with Seasonal and Perennial Allergic Rhinitis

JERUSALEM–(BUSINESS WIRE)–Dec. 19, 2014– Teva Pharmaceutical Industries Ltd., announced today that the U.S. Food and Drug Administration (FDA) approved QNASL (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us